This study will assess the short term efficacy of ibandronate (6 mg intravenous \[IV\]) in participants with breast cancer and malignant bone disease, with moderate to severe pain. All participants will receive an IV infusion of ibandronate on Days 1, 2, and 3, and pain response will be measured on Days 1-7. The anticipated time on study treatment is 3 days, and the target sample size is 182 individuals.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
182
Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
Unnamed facility
Budapest, Hungary
Unnamed facility
Budapest, Hungary
Unnamed facility
Budapest, Hungary
Unnamed facility
Budapest, Hungary
Percentage of participants with >=25% reduction in mean pain
Time frame: up to Day 6
Percentage of participants with =<35% increase in mean analgesic consumption
Time frame: up to Days 7
Change from Baseline in average pain score
Time frame: Baseline (Days 0), 5, and 7
Analgesic consumption
Time frame: up to Day 7
Pain response
Time frame: up to Day 7
Time to pain response
Time frame: up to Day 7
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Budapest, Hungary
Unnamed facility
Budapest, Hungary
Unnamed facility
Győr, Hungary
Unnamed facility
Gyula, Hungary
Unnamed facility
Kecskemét, Hungary
Unnamed facility
Nyíregyháza, Hungary
...and 5 more locations